Keros Therapeutics reported net income of -$28.71M for the quarter ended Jun 2026. This income statement covers 29 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||
| Revenue | 0.10M | 20.00M | 18.00M | 0.01M | 0.14M | 0.08M | 0.04M | 0.39M | 3.04M | 211.25M | 18.17M | 14.26M | 0.39M | ||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.98M | 14.83M | 18.83M | 18.08M | 23.28M | 21.04M | 24.87M | 31.09M | 32.53M | 34.14M | 37.49M | 38.26M | 40.52M | 49.23M | 45.63M | 48.71M | 43.50M | 19.52M | 17.91M | 22.33M | |||||||||
| Selling, General & AdministrativeSG&A | 5.66M | 5.37M | 6.03M | 6.05M | 7.45M | 6.94M | 7.09M | 7.78M | 8.80M | 9.15M | 9.11M | 10.31M | 9.96M | 9.82M | 10.66M | 10.50M | 14.48M | 10.13M | 11.74M | 8.61M | |||||||||
| Other Operating ExpensesOther Opex | |||||||||||||||||||||||||||||
| Operating ExpensesOpex | 15.64M | 20.20M | 24.87M | 24.13M | 30.73M | 27.98M | 31.96M | 38.87M | 41.34M | 43.29M | 46.60M | 48.57M | 50.48M | 59.05M | 56.30M | 59.21M | 57.98M | 29.65M | 29.66M | 30.94M | |||||||||
| Operating IncomeOp. Inc | -15.54M | -20.20M | -4.87M | -24.13M | -30.73M | -27.98M | -31.96M | -38.87M | -41.34M | -43.28M | -46.45M | -48.48M | -50.44M | -58.66M | -53.25M | 152.04M | -39.82M | -15.38M | -29.27M | -30.94M | |||||||||
| EBIT | -15.54M | -20.20M | -4.87M | -24.13M | -30.73M | -27.98M | -31.96M | -38.87M | -41.34M | -43.28M | -46.45M | -48.48M | -50.44M | -58.66M | -53.25M | 152.04M | -39.82M | -15.38M | -29.27M | -30.94M | |||||||||
| Non-operating items | |||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.00M | 0.00M | 0.00M | 0.00M | |||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.08M | -0.14M | -0.10M | -0.06M | 0.09M | 0.76M | -1.40M | -0.04M | -0.15M | -0.07M | 0.06M | -0.44M | -0.20M | -0.09M | -0.23M | -0.34M | -0.22M | -0.25M | 0.27M | -0.06M | |||||||||
| Non Operating IncomeNon Op. Inc. | -0.08M | -0.14M | -0.07M | -0.06M | 3.46M | 4.47M | 2.24M | 3.06M | 3.83M | 3.84M | 6.21M | 5.37M | 5.18M | 5.70M | 7.53M | 6.45M | 6.90M | 6.68M | 4.29M | 2.23M | |||||||||
| Net income details | |||||||||||||||||||||||||||||
| EBT | -15.62M | -20.34M | -4.94M | -24.19M | -27.27M | -23.51M | -29.72M | -38.87M | -41.34M | -43.28M | -46.45M | -43.11M | -45.26M | -52.96M | -45.73M | 158.49M | -32.92M | -8.70M | -24.98M | -28.71M | |||||||||
| Tax ProvisionsTaxes | -0.04M | 2.00M | 0.30M | 10.04M | -2.22M | -1.42M | -1.51M | ||||||||||||||||||||||
| Profit After TaxPAT | -15.62M | -20.30M | -6.94M | -24.19M | -27.27M | -23.51M | -29.72M | -35.80M | -37.51M | -39.44M | -40.24M | -43.11M | -45.26M | -52.96M | -46.03M | 148.45M | -30.70M | -7.28M | -23.46M | -28.71M | |||||||||
| Income from Continuing OperationsIncome (Continuing) | -15.62M | -20.30M | -6.94M | -24.19M | -27.27M | -23.51M | -29.72M | -38.87M | -41.34M | -43.28M | -46.45M | -43.11M | -45.26M | -52.96M | -46.03M | 148.45M | -30.70M | -7.28M | -23.46M | -28.71M | |||||||||
| Consolidated Net IncomeConsol Net Inc. | -15.62M | -20.30M | -6.94M | -24.19M | -27.27M | -23.51M | -29.72M | -38.87M | -41.34M | -43.28M | -46.45M | -43.11M | -45.26M | -52.96M | -46.03M | 148.45M | -30.70M | -7.28M | -23.46M | -28.71M | |||||||||
| Income towards Parent CompanyParent Net Inc | -15.62M | -20.30M | -6.94M | -24.19M | -27.27M | -23.51M | -29.72M | -38.87M | -41.34M | -43.28M | -46.45M | -43.11M | -45.26M | -52.96M | -46.03M | 148.45M | -30.70M | -7.28M | -23.46M | -28.71M | |||||||||
| Net Income towards Common StockholdersNet Income | -15.62M | -20.30M | -6.94M | -24.19M | -27.27M | -23.51M | -29.72M | -35.80M | -37.51M | -39.44M | -40.24M | -43.11M | -45.26M | -52.96M | -46.03M | 148.45M | -30.70M | -7.28M | -23.46M | -28.71M | |||||||||
| Additional items | |||||||||||||||||||||||||||||
| EPS (Basic) | -0.67 | -0.87 | -0.30 | -1.01 | -1.13 | -0.92 | -1.18 | -1.26 | -1.27 | -1.33 | -1.37 | -1.21 | -1.25 | -1.41 | -1.23 | 3.66 | -0.76 | -0.18 | -0.63 | -1.45 | |||||||||
| EPS (Diluted) | -0.67 | -0.87 | -0.30 | -1.01 | -1.13 | -0.92 | -1.18 | -1.26 | -1.27 | -1.33 | -1.37 | -1.21 | -1.25 | -1.41 | -1.23 | 3.62 | -0.76 | -0.18 | -0.62 | -1.45 | |||||||||
| Shares Outstanding | 23.31M | 23.36M | 23.33M | 23.99M | 24.05M | 25.55M | 25.24M | 28.37M | 29.60M | 29.67M | 29.45M | 35.69M | 36.10M | 37.59M | 37.44M | 40.56M | 40.61M | 40.62M | 37.22M | 19.80M | |||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 23.31M | 23.36M | 23.33M | 23.99M | 24.05M | 25.55M | 25.24M | 28.37M | 29.60M | 29.67M | 29.45M | 35.69M | 36.10M | 37.59M | 37.44M | 41.02M | 40.61M | 40.62M | 37.86M | 19.80M | |||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 23.33M | 23.40M | 23.97M | 24.00M | 24.43M | 26.08M | 27.54M | 29.55M | 29.66M | 29.68M | 31.84M | 36.07M | 36.17M | 39.26M | 40.55M | 40.56M | 40.62M | 40.63M | 37.22M | 19.83M | |||||||||
| EBITDA | -15.54M | -20.20M | -4.87M | -24.13M | -30.73M | -27.98M | -31.96M | -38.87M | -41.34M | -43.28M | -46.45M | -48.48M | -50.44M | -58.66M | -53.25M | 152.04M | -39.82M | -15.38M | -29.27M | -30.94M | |||||||||
| Interest ExpensesInt Expense | 0.00M | 0.00M | 0.00M | 0.00M | |||||||||||||||||||||||||
| Tax Rate | 0.19% | -40.46% | -0.66% | 6.34% | 6.75% | 16.36% | 6.06% |